After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

It is widely accepted that sugar and foods high in sugar will make a child or young person hyperactive and extremely energetic. However, research conducted over the last 20 years has shown that sugar ...

Suven Life Sciences has a portfolio of advanced-stage clinical candidates and research programs designed for CNS disorders ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Teams from various departments have sprung into action to prevent and control vector-borne diseases like dengue, malaria, and ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Adults with congenital adrenal hyperplasia treated with an oral nonsteroidal drug saw continued disease control with reduced ...

Chronic inflammation, already tied to heart disease and cancer, may also worsen the emotional toll of poor sleep. A new UCLA ...

OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

Daily use of diversified segmental defocus optimization (DSDO) spectacle lenses delays the onset of myopia among children, ...

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their ...